Ron Waksman1, Paige E Craig2, Rebecca Torguson2, Federico M Asch3, Gaby Weissman4, Daniel Ruiz2, Paul Gordon5, Afshin Ehsan6, Puja Parikh7, Thomas Bilfinger8, Robert Levitt9, Chiwon Hahn10, David Roberts11, Michael Ingram11, Nicholas Hanna12, George Comas13, Cheng Zhang2, Itsik Ben-Dor2, Lowell F Satler2, Hector M Garcia-Garcia2, Christian Shults14, Toby Rogers15. 1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia. Electronic address: ron.waksman@medstar.net. 2. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia. 3. MedStar Health Research Institute, MedStar Washington Hospital Center, Washington, District of Columbia. 4. Department of Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia. 5. Division of Cardiology, The Miriam Hospital, Providence, Rhode Island. 6. Division of Cardiothoracic Surgery, Lifespan Cardiovascular Institute, Providence, Rhode Island. 7. Department of Medicine, Stony Brook Hospital, Stony Brook, New York. 8. Department of Surgery, Stony Brook Hospital, Stony Brook, New York. 9. Department of Cardiology, Henrico Doctors' Hospital, Richmond, Virginia. 10. Department of Cardiothoracic Surgery, Henrico Doctors' Hospital, Richmond, Virginia. 11. Sutter Medical Center, Sacramento, Sutter Heart and Vascular Institute, Research, Sacramento, California. 12. St. John Heart Institute Cardiovascular Consultants, St. John Health System, Tulsa, Oklahoma. 13. St. John Clinic Cardiovascular Surgery, St. John Heart Institute Cardiovascular Consultants, St. John Health System, Tulsa, Oklahoma. 14. Department of Cardiac Surgery, MedStar Washington Hospital Center, Washington, District of Columbia. 15. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia; Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Abstract
OBJECTIVES: The aim of this study was to evaluate clinical outcomes and transcatheter heart valve hemodynamic parameters after transcatheter aortic valve replacement (TAVR) in low-risk patients with bicuspid aortic stenosis (AS). BACKGROUND:TAVR is approved for low-risk patients in the United States. However, patients with bicuspid AS were excluded from the randomized cohorts of the pivotal low-risk trials. METHODS: The LRT (Low Risk TAVR) trial was an investigator-initiated, prospective, multicenter study and was the first and only U.S. Food and Drug Administration-approved investigational device exemption trial to evaluate the feasibility of TAVR with either balloon-expandable or self-expanding valves in low-risk patients with bicuspid AS. The primary endpoint was all-cause mortality at 30 days. Baseline and follow-up echocardiography and computed tomography to detect leaflet thickening were analyzed in an independent core laboratory. RESULTS:Sixty-one low-risk patients with symptomatic, severe AS and bicuspid aortic valves (78.3% Sievers type 1 morphology) underwent TAVR at 6 centers from 2016 to 2019. The mean age was 68.6 years, and 42.6% were men. At 30 days, there was zero mortality and no disabling strokes. The rate of new permanent pacemaker implantation was 13.1%; just 1 patient had a moderate paravalvular leak at 30 days. Hypoattenuated leaflet thickening was observed in 10% of patients at 30 days. CONCLUSIONS:TAVR appears to be safe in patients with bicuspid AS, with short length of hospital stay, zero mortality, and no disabling strokes at 30 days. Subclinical leaflet thrombosis was observed in a minority of patients at 30 days but did not appear to be associated with clinical events.
RCT Entities:
OBJECTIVES: The aim of this study was to evaluate clinical outcomes and transcatheter heart valve hemodynamic parameters after transcatheter aortic valve replacement (TAVR) in low-risk patients with bicuspid aortic stenosis (AS). BACKGROUND: TAVR is approved for low-risk patients in the United States. However, patients with bicuspid AS were excluded from the randomized cohorts of the pivotal low-risk trials. METHODS: The LRT (Low Risk TAVR) trial was an investigator-initiated, prospective, multicenter study and was the first and only U.S. Food and Drug Administration-approved investigational device exemption trial to evaluate the feasibility of TAVR with either balloon-expandable or self-expanding valves in low-risk patients with bicuspid AS. The primary endpoint was all-cause mortality at 30 days. Baseline and follow-up echocardiography and computed tomography to detect leaflet thickening were analyzed in an independent core laboratory. RESULTS: Sixty-one low-risk patients with symptomatic, severe AS and bicuspid aortic valves (78.3% Sievers type 1 morphology) underwent TAVR at 6 centers from 2016 to 2019. The mean age was 68.6 years, and 42.6% were men. At 30 days, there was zero mortality and no disabling strokes. The rate of new permanent pacemaker implantation was 13.1%; just 1 patient had a moderate paravalvular leak at 30 days. Hypoattenuated leaflet thickening was observed in 10% of patients at 30 days. CONCLUSIONS: TAVR appears to be safe in patients with bicuspid AS, with short length of hospital stay, zero mortality, and no disabling strokes at 30 days. Subclinical leaflet thrombosis was observed in a minority of patients at 30 days but did not appear to be associated with clinical events.
Authors: Tian-Yuan Xiong; Walid Ben Ali; Yuan Feng; Kentaro Hayashida; Hasan Jilaihawi; Azeem Latib; Michael Kang-Yin Lee; Martin B Leon; Raj R Makkar; Thomas Modine; Christoph Naber; Yong Peng; Nicolo Piazza; Michael J Reardon; Simon Redwood; Ashok Seth; Lars Sondergaard; Edgar Tay; Didier Tchetche; Wei-Hsian Yin; Mao Chen; Bernard Prendergast; Darren Mylotte Journal: Nat Rev Cardiol Date: 2022-06-20 Impact factor: 32.419
Authors: Ole de Backer; Tobias Zeus; Verena Veulemans; Philippe Nuyens; Shouheng Goh; Oliver Maier; Stephan Binnebößel; Jacqueline Heermann; Christian Jung; Ralf Westenfeld; Malte Kelm Journal: Clin Res Cardiol Date: 2022-06-29 Impact factor: 5.460
Authors: Xiling Zhang; Thomas Puehler; Derk Frank; Janarthanan Sathananthan; Stephanie Sellers; David Meier; Marcus Both; Philipp Blanke; Hatim Seoudy; Mohammed Saad; Oliver J Müller; Lars Sondergaard; Georg Lutter Journal: J Cardiovasc Dev Dis Date: 2022-07-12